Navigation Links
Orexigen® Therapeutics Reports Third Quarter Financial Results
Date:11/8/2011

bmission of an NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to attract and retain key personnel; Orexigen's ability to raise and maintain sufficient capital; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q, which we intend to file with the Securities Exchange Commission this week and will be available from the SEC's website (www.sec.gov) and on our website (www.orexigen.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.Orexigen Therapeutics, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months Ended September 30, September 30, 2011201020112010Revenues:Collaborative agreement $

857$

286$

2,571$

286License revenue 02297166Total revenues 8573083,542352Operating expenses:Research and development 1,5398,18611,23721,753General and administrative 3,9076,62415,87018,827Total operating expenses 5,44614,81027,10740,580Loss from operations (4,589)(14,502)(23,565)(40,228)Other income (expense):Interest income 92135101Interest expense -(165)(221)(501)Total other income (expense) 9(144)(186)(400)Net loss $

(4,580)$

(14,646)$

(23,751)$

(40,628)Net loss per share - basic and diluted $

(0.10)$

(0.31)$

(0.
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
4. Orexigen® Therapeutics Announces Corporate Realignment
5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
6. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
7. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- Two years after its founding by a community of ... Oakland -based Counter Culture Labs (CCL) has ... democratize science through a full-fledged community laboratory space in ... Photo - http://photos.prnewswire.com/prnh/20150526/218366LOGO ... out of the new Omni Commons , a ...
(Date:5/27/2015)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... innovative therapies primarily in the areas of dermatology ... of the Company,s Series A and Series A-1 ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March 31, ... Series A Preferred Stock and Series A-1 Preferred ...
(Date:5/26/2015)... Canada, and BELLINGHAM, Washington, USA (PRWEB) May 26, 2015 ... has signed a formal partnership with the Max ... Centre for Extreme and Quantum Photonics. The center will ... the field of photonics, and will be only the ... CEO of SPIE, the international society for optics ...
(Date:5/26/2015)... May 26, 2015 Innovacyn, a ... in the human and animal health industries, announced ... Future Innovators of Agriculture College Scholarship Award. The ... who exhibits a passionate commitment to the agriculture ... This year’s winners, Alexis Pedrow from Anderson County ...
Breaking Biology Technology:East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3
... Pa., May 28 Centocor Ortho Biotech Products, L.P. ... be presented at the 45th American Society of Clinical ... 29 to June 2, 2009. The studies were ... research partner, Ortho Biotech Oncology Research and Development, a ...
... patient was supported with the,Berlin Heart EXCOR(R) Pediatric Ventricular ... first implantation of the device in 1990. The,patient, an ... in Chicago and has been successfully transplanted in the ... diagnosed a few weeks after birth with left,ventricular non ...
... Association (DIA) today announced its new 45th Annual Meeting Online. For the ... Meeting. , ... Horsham, PA (Vocus) May 28, 2009 -- The ... Meeting Online . For the first time ever, DIA now offers live ...
Cached Biology Technology:Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 7Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 8Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 9Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 10Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 11500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device 2Drug Information Association Launches New 45th Annual Meeting Online 2Drug Information Association Launches New 45th Annual Meeting Online 3
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
(Date:5/21/2015)... , May 21, 2015 The ... potential of music for health, today announced a collaborative ... . The partnership will center on collaboration on original ... a first step in the collaboration, The Sync Project ... on "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Simplifying the process for forming compounds that can be ... plastics, has earned one University of Houston chemist a ... of chemistry in the College of Natural Sciences and ... mathematicians and economists in the United States and Canada ...
... productive as conventional systems" The answer is an unqualified, ... most of the time for corn and soybeans according ... Wisconsin-Madison and agricultural consulting firm AGSTAT in the March-April ... their answer on results from the Wisconsin Integrated Cropping ...
... biosensing nanodevice developed by Arizona State University researcher ... security checkpoints and revolutionize health screenings for diseases ... (MRSA). Even more incredible than the device ... worlds tiniest rotary motor: a biological engine measured ...
Cached Biology News:Simplifying manufacture of drugs, plastics earns UH chemist top honor 2Are organic crops as productive as conventional? 2Biosensing nanodevice to revolutionize health screenings 2Biosensing nanodevice to revolutionize health screenings 3
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Sheep polyclonal to Salmonella Thomasville ( Abpromise for all tested applications). Antigen: Native Salmonella thomasville...
anti-achaete...
... ( Abpromise for all tested applications). ... KLH derived from within residues 1 - 100 ... sequence is proprietary) (Peptide available ... Gene ID: 5453 Swiss ...
Biology Products: